Fig. 2From: Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravirDrug dose escalations (mean ± SEM) reflect the differential emergence of resistance to integrase inhibitors by recombinant strains encoding patient-derived integrase with (n = 5) and without (n = 5) the E157Q resistance substitutionBack to article page